Grifols (A) (Seite 9)

[bonDiacomova]

From this page you can get access to the notifications of voting rights
and financial instruments sent by the obliged persons.

Significant shareholders

https://www.cnmv.es/portal/Consultas/DerechosVoto/Notificaci…

[bonDiacomova]

BlackRock hat der National Securities Market Commission (CNMV) am Dienstag
eine Aufstockung seiner Position in Grifols gemeldet, mit der es 3,83 % der Aktien
des katalanischen Unternehmens erreicht. Der Investmentmanager hat seine Position
um 0,24 Punkte aufgestockt, ein Paket im Marktwert von rund 10 Millionen.

https://www.capitalmadrid.com/2022/12/7/63937/blackrock-cons…

short aufgestockt - AKO Capital LLP auf 0,72
https://www.cnmv.es/portal/Consultas/EE/PosicionesCortas.asp…

[bonDiacomova]

Grifols vuela en Bolsa al calor de las valoraciones de Morgan Stanley y JP Morgan

Grifols fliegt an der Börse im Eifer der Bewertungen von Morgan Stanley und JP Morgan

Morgan Stanley precio objetivo pasa de 13 a 14
JP Morgan precio objetivo .... de 15 a 12 euros

https://www.estrategiasdeinversion.com/analisis/los-brokers-…

[bonDiacomova]

Biotest erhält Zulassung für Yimmugo

Die Biotest AG gibt heute bekannt, dass die in Deutschland zuständige Behörde,
das Paul-Ehrlich-Institut, das neue intravenöse Immunglobulin Yimmugo®
(IgG Next Generation) in Deutschland zugelassen hat.

„Die Markteinführung von Yimmugo® in Deutschland wird noch im Dezember dieses Jahres beginnen.“

Der Zulassung in Deutschland ging das kürzlich erfolgreich abgeschlossene dezentrale Verfahren in Deutschland und Österreich voran, das Biotest im März 2022 eingereicht hat. Das Zulassungsverfahren wurde in weniger als 7 Monaten erfolgreich beendet. Die Zulassung in Österreich steht ebenfalls unmittelbar bevor. Weitere Zulassungen in europäischen und außereuropäischen Ländern sind geplant.

https://www.pressebox.de/inaktiv/biotest-ag/Biotest-erhaelt-…

[bonDiacomova]

Grifols S A : First half 2022 earnings release

Grifols' business momentum delivers EUR 2,810 million in revenues and
EUR 618 million in EBITDA as plasma collections accelerate

EBITDA sequentially improves to EUR 618 million, with a 22.0% margin (22.8% excluding Biotest),
driven by revenue growth, operational leverage and effective operational cost control

Net profit totals EUR 144 million, reflecting higher financial expenses linked with Biotest acquisition

https://www.marketscreener.com/quote/stock/GRIFOLS-S-A-25530…

[bonDiacomova]

Biotest AG: Biotest reports sales of Euro 361 million in the first nine months of 2022
https://www.marketscreener.com/quote/stock/BIOTEST-AG-435776…

[bonDiacomova]

Q3 revenues grow by 23% cc and 37% on a reported basis to EUR 1,541 million
driven by Biopharma (EUR 1,265 million; +34% cc; +49% reported)

Robust Q3 growth leads to total revenues of EUR 4,351 million,
increasing by 9.5% cc (+18.8% reported) in the first nine months of 2022

Plasma collection volumes grow by 25% YTD; focused on increasing efficiency with lower cost per liter

Reported EBITDA totals EUR 927 million, representing a 21.3% margin (22.2% excluding Biotest),
driven by revenue growth, operational leverage and cost discipline

Net profit totals EUR 188 million, reflecting higher financial expenses linked with Biotest acquisition

Reported leverage ratio declines to 8.6x, while it is expected to further decline to 7.9x at year-end 2022

Grifols is laser-focused on improving cash flow and expense profile, reducing debt, capturing commercial opportunities,
unlocking Biotest's substantial value, and streamlining the organization

The company is on track to deliver on its financial commitments for FY2022, with record revenues
in the range of EUR 5.8 to 6.0bn and adjusted EBITDA margin of 20-21%

https://www.marketscreener.com/quote/stock/GRIFOLS-S-A-25530…

[bonDiacomova]

BARCELONA, Spain, Nov. 3, 2022 /PRNewswire/ -- Grifols (MCE: GRF) (MCE:GRF.P) (NASDAQ:GRFS), a global leader in plasma-derived medicines and innovative diagnostic solutions, today announced that its AlphaID™ At Home Genetic Health Risk Service, the first-ever free direct-to-consumer program in the U.S. to screen for genetic risk of alpha1-antitrypsin deficiency (alpha-1), has been cleared by the U.S. Food and Drug Administration (FDA).

https://www.prnewswire.com/news-releases/grifols-receives-fd…

[bonDiacomova]

An Intrinsic Calculation For Grifols, S.A. (BME:GRF) Suggests It's 45% Undervalued

Simply Wall St https://simplywall.st/stocks/es/pharmaceuticals-biotech/bme-…

The Calculation : We are going to use a two-stage DCF model...

[bonDiacomova]

Grifols says U.S. blood donors' lawsuit won't have material impact, shares down

The company said about 54,000 donors in Illinois had filed a lawsuit claiming Grifols
breached data protection regulations, confirming the newspaper report.

The company said its legal team recommended not to make a provision for the outcome of the lawsuit
as potential liabilities associated with the case were insured, and
it said it believed it had arguments backing its position.

quelle https://www.reuters.com/markets/europe/grifols-says-us-blood…